Drug profile · INN
recombinant human c1 inhibitor
RHUCIN
recombinant human c1 inhibitor (RHUCIN) is a plasma protease c1 inhibitor exogenous protein.
EMA: refused Blood and blood forming organs (B06) B06C
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — recombinant human c1 inhibitor
- Class
- Blood and blood forming organs (B06)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
recombinant human c1 inhibitor (RHUCIN) is a plasma protease c1 inhibitor exogenous protein.
Key facts
INN recombinant human c1 inhibitor
Brand RHUCIN
Mechanism Plasma protease C1 inhibitor exogenous protein
Target Plasma protease C1 inhibitor
Therapeutic class Blood and blood forming organs (B06)
ATC code B06C
Mechanism of action
Plasma protease C1 inhibitor exogenous protein
Primary target: Plasma protease C1 inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | refused | — |
Related & competitor drugs
Frequently asked questions
What is recombinant human c1 inhibitor?
recombinant human c1 inhibitor (RHUCIN) is a plasma protease c1 inhibitor exogenous protein.
What is the brand name for recombinant human c1 inhibitor?
RHUCIN is a marketed brand name for recombinant human c1 inhibitor. Check FDA Drugs@FDA for the current US label holder and prescribing information.